Abstract
RATIONALE: Subcutaneous (SC) administration of IgG is limited by large volume delivery requirements that translate into a weekly dosing regimen with multiple injection sites. Decreasing formulation volume by increasing IgG concentration increases viscosity and resistance to flow, resulting in increased demands on delivery hardware such as infusion pumps and needle sets. This work examines delivery hardware and the use of recombinant human hyaluronidase to minimize these challenges.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
